Mark Avagliano Net Worth

Insider trading at G1 Therapeutics

Over the last 2 years, insiders at G1 Therapeutics have traded over $51,509,269 worth of G1 Therapeutics stock and bought 1,482,753 units worth $23,467,604 . The most active insider traders include Capital Management, Llcra C…, Fredric N Eshelman, and Glenn P Muir. On average, G1 Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $994,813. The most recent stock trade was executed by Jennifer K. Moses on 18 July 2019, trading 2,000 units of GTHX stock currently worth $7,440.

What does G1 Therapeutics do?

G1 Therapeutics, Inc. develops drugs for cancer treatment. It is a clinical-stage biopharmaceutical company that focuses on the discovery and development of novel therapies to address significant unmet needs in oncology. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

What does G1 Therapeutics’s logo look like?

G1 Therapeutics executives and stock owners

G1 Therapeutics executives and other stock owners filed with the SEC include:

  • John Demaree, Chief Commercial Officer
  • James Hanson, General Counsel
  • Terry Murdock, Chief Operating Officer
  • Mark Velleca, President, Chief Executive Officer, Director
  • Garry Nicholson, Independent Chairman of the Board
  • Barclay Phillips, Chief Financial Officer and Senior Vice President – Corporate Development
  • Rajesh Malik, Chief Medical Officer, Senior Vice President – Research and Development
  • Cynthia Schwalm, Independent Director
  • Willie Deese, Independent Director
  • Seth Rudnick, Independent Director
  • Glenn Muir, Independent Director
  • Fredric Eshelman, Independent Director
  • Andrew Witty, Independent Director
  • Jeff Macdonald, Head of Investor Relations/Public Relations
  • Jennifer Moses, Vice President – Finance and Accounting
  • Jay Strum, Chief Scientific Officer
  • Clay Hatteras Venture Advis…,
  • Capital Management, Llcra C…,
  • Christy L Shaffer, Director
  • Ventures, Inc. Med Immune, 10% owner
  • Ventures, Llc Eshelman, 10% owner
  • Clay Hatteras Venture Advis…,
  • Mark Avagliano, Chief Business Officer